Deep Vein Thrombosis; A Paradigm Change in Treatment through Drug-Free Clot Removal

Descripción del proyecto

El tratamiento de coágulos sanguíneos potencialmente mortales pronto podría ser más fácil y menos caro

Una piedra en el riñón es dolorosa, pero raramente resulta mortal. Su tratamiento incluye desde simplemente beber mucha agua hasta la cirugía en los casos complicados. Sin embargo, cuando se trata de coágulos en las venas profundas del cuerpo (trombosis venosa profunda), la situación es muy diferente. Los grandes coágulos pueden desprenderse y alojase en las arterias pulmonares y bloquearlas con consecuencias, a menudo, letales. Los medicamentos trombolíticos potentes administrados durante las largas estancias en los hospitales siguen siendo el tratamiento de referencia, pero se relacionan con un riesgo considerablemente mayor de hemorragia. VETEX está lanzando al mercado un nuevo tratamiento revolucionario que facilita la extracción de coágulos y minimiza el uso de medicamentos trombolíticos. Su éxito reducirá la carga para los sistemas sanitarios y mejorará la vida de millones de personas.

Objetivo

Deep Vein Thrombosis is the 3rd leading cardiovascular disease behind heart attack and stroke with 1.2M cases diagnosed each year in the EU and US.

Left untreated, one third of DVT patients will be at risk of clot breaking away causing a Pulmonary Embolism which has a 50% mortality rate. In addition, significant chronic complications often occur such as clot recurrence (30%), chronic limb swelling associated with Post Thrombotic Syndrome (50%), ulceration and amputation.

DVT patients are usually treated with drugs. Anticoagulation therapy alone helps prevent clot extension but it does not remove the clot. Other therapies often involve long hospital stays and often require 24-72 hours in ICU due to the significant bleeding risks associated with heavier duty clot busting (Thrombolytic) drugs. The results are poor for patients with large occulsive clots and who are at risk of bleeding, and extremely expensive for healthcare providers.

Vetex Medical is an early stage medical device based in Ireland that has developed a platform technology that rapidly removes high volumes of clot form the deep veins without the use of thrombolytic drugs, and so will radically challenge the inefficiencies and economics present in the current management of deep vein thrombosis.

Deep Vein Thrombosis in the larger veins of the upper limb represents $600m market opportunity. Interventions in the treatment of DVT have been increasing steadily over the last number of years with growth rates of 15%. This market segment is increasingly ‘on trend’ and set to witness expedited growth over the coming years.

Vetex Medical is ambitious in its’ plan to bring the FreeFlow technology to market in both Europe and the US in 2021, through completion of a Clinical Trial and through securing regulatory approvals to allow market entry. The Vetex Medical Team has the skills and experience to develop and commercialise this novel medical technology and to implement a high
growth strategy.

Ámbito científico

Programa(s)

Tema(s)

EIC-SMEInst-2018-2020 - SME instrument

Convocatoria de propuestas

H2020-EIC-SMEInst-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEInst-2018-2020-2

Régimen de financiación

SME-2 - SME instrument phase 2

Coordinador

VETEX MEDICAL LIMITED

Aportación neta de la UEn

€ 2 485 644,00

Dirección

218 BUSINESS INNOVATION CENTRE, NUIG
H91 FC85 GALWAY
Irlanda

Pyme

Sí

Región

Ireland Northern and Western West

Tipo de actividad

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Enlaces

Contactar con la organización

Participación en los programas de I+D de la UE

Red de colaboración de HORIZON

Coste total

€ 3 550 920,00